New Market Research Report: Slovakia Pharmaceuticals & Healthcare Report Q1 2014

Nationalisation of the two largest, private health insurers have seen further setbacks as the treasury states that there is not enough funding to purchase majority stakes from shareholders and integrate them into the state insurer. We believe Prime Minister Robert Fico's government is losing the momentum to push through the changes needed to bring about the nationalisation, and therefore now believe it unlikely to go ahead. We forecast further generic uptake and greater co-payments by patients towards the cost of healthcare, in line with an established trend we see playing out in Eastern Europe. We believe growth in pharmaceutical spending will be weak as resources will be focused in long-term care and healthcare services as Slovakia's ageing population increases its demand on the healthcare system.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/754768_slovakia_pharmaceuticals_healthcare_report_q1.aspx?afid=301

* Pharmaceuticals: EUR1.67bn (US$2.12bn) in 2012 to EUR1.67bn (US$2.22bn) in 2013; -0.2% in local currency terms and 4.5% in US dollar terms. Figures unchanged from Q413.
* Healthcare: EUR6.29bn (US$7.99bn) in 2012 to EUR6.47bn (US$8.61bn) in 2013; +2.8% in local currency terms and 7.7% in US dollar terms. Slight revision upward owing to better than expected GDP growth figures and rising private healthcare spending.

Risk/Reward Rating: Slovakia's Risk rating indicates the country has one of the best business environments in the Central and Eastern European region, but its ranking is moderated by its less-than-stellar rewards score. Consequently, Slovakia has a RRR score of 54 out of 100, making it the seventh-most attractive pharmaceutical market in Central and Eastern Europe.

Key Trends And Developments

* Budgetary conflicts and a lack of political will indicates that the nationalisation of the two largest private health insurers is unlikely to be go through in the short term.
* The International Court of Arbitration ruled in favour of Dutch-owned private health insurer Union, after Robert Fico's government banned health insurers from turning a profit. Although not legally binding, the decision sets a precedent for rulings from the EU Commissioner, who may strike down on Slovakia's measures.
* The government has increased the level of private contributions towards the cost of reimbursed medicines, as it seeks to continue its plan to curtail pharmaceutical expenditure.
* Pharmaceutical spending will be moderated at the expense of providing care and essential services in the short term.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Malaysia Pharmaceuticals & Healthcare Report Q1 2014
- Russia Pharmaceuticals & Healthcare Report Q1 2014
- Sweden Pharmaceuticals & Healthcare Report Q1 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2014
- Estonia Pharmaceuticals & Healthcare Report Q1 2014